This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: The Bulls Are in Charge

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK ( TheStreet) -- Bear markets create problems but bull markets solve them, Jim Cramer told "Mad Money" viewers Wednesday. Cramer compared the prevailing wisdom of just four months ago against the realities of today.

Cramer said that back in December there were five things the bears were preaching: The federal government was about to fall off a cliff, the Federal Reserve was going to slow its bond buying and problems in Europe were back on the radar. If those didn't kill us, then surely the debt ceiling and sequester would and, if not, fourth-quarter earnings would certainly be miserable.

Cramer said all of these notions seemed perfectly plausible back then, but reality played out in a starkly different manner. Earnings turned out to be some of the best we've seen in 15 years.

Meanwhile, the markets simply stopped being worried about Washington or Europe. Our tax code didn't change all that much and the Fed won't be slowing its stimulus until employment picks up. The sequester has been a dud thus far and continued gridlock in Washington has been a boon for the markets.

It's time to embrace the future, Cramer concluded, as the markets focus on the future, not the past. The bulls are in charge and those remaining bears are just costing investors money.

A Pharma Dividend Play

All Big Pharma names are not created equal, Cramer told viewers, as he highlighted GlaxoSmithKline (GSK) as the next stock in this week's focus on the sector. He said that Glaxo is not a breakup story, nor a catch-up stock, but a good, old-fashioned dividend play with a juicy 5.8% yield.

Cramer said that while a big yield is sometimes a red flag, that's not the case with Glaxo now that its legal issues are largely behind it. The company just reached a $3 billion settlement over the advertising of some of its anti-depressant drugs and it has a huge pipeline of new drugs.

Glaxo is set to seek approval for 15 drugs, some of them blockbusters, over the next three years. Everything from new asthma treatments to cancer drugs and heart therapies will be coming from the company in fairly short order. That translates into an 8.4% compound growth rate through 2018, said Cramer.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,265.99 +109.14 0.64%
S&P 500 2,011.36 +9.79 0.49%
NASDAQ 4,593.4250 +31.2360 0.68%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs